[1]
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA, American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American journal of respiratory and critical care medicine. 2003 Feb 15:167(4):603-62
[PubMed PMID: 12588714]
[2]
Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clinics in chest medicine. 2019 Dec:40(4):839-848. doi: 10.1016/j.ccm.2019.07.008. Epub
[PubMed PMID: 31731988]
[3]
Ross JM, Badje A, Rangaka MX, Walker AS, Shapiro AE, Thomas KK, Anglaret X, Eholie S, Gabillard D, Boulle A, Maartens G, Wilkinson RJ, Ford N, Golub JE, Williams BG, Barnabas RV. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. The lancet. HIV. 2021 Jan:8(1):e8-e15. doi: 10.1016/S2352-3018(20)30299-X. Epub
[PubMed PMID: 33387480]
Level 1 (high-level) evidence
[4]
Lanzafame M, Vento S. Mini-review: Silico-tuberculosis. Journal of clinical tuberculosis and other mycobacterial diseases. 2021 May:23():100218. doi: 10.1016/j.jctube.2021.100218. Epub 2021 Feb 2
[PubMed PMID: 33598569]
[5]
Mamani M, Majzoobi MM, Torabian S, Mihan R, Alizadeh K. Latent and active tuberculosis: evaluation of injecting drug users. Iranian Red Crescent medical journal. 2013 Sep:15(9):775-9. doi: 10.5812/ircmj.6283. Epub 2013 Sep 5
[PubMed PMID: 24616784]
[6]
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Aug 14:71(4):e1-e36. doi: 10.1093/cid/ciaa241. Epub
[PubMed PMID: 32628747]
Level 1 (high-level) evidence
[7]
Chakraborty S, Rhee KY. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. Cold Spring Harbor perspectives in medicine. 2015 Apr 15:5(8):a021147. doi: 10.1101/cshperspect.a021147. Epub 2015 Apr 15
[PubMed PMID: 25877396]
Level 3 (low-level) evidence
[8]
Ghodousi A, Tagliani E, Karunaratne E, Niemann S, Perera J, Köser CU, Cirillo DM. Isoniazid Resistance in Mycobacterium tuberculosis Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms. Antimicrobial agents and chemotherapy. 2019 Jul:63(7):. doi: 10.1128/AAC.00092-19. Epub 2019 Jun 24
[PubMed PMID: 31010866]
[9]
Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, Zhu Y, Liu B, Zhou Y, Yang J, Zhao Y, Jin Q, Zhang X. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerging microbes & infections. 2018 Nov 16:7(1):183. doi: 10.1038/s41426-018-0184-0. Epub 2018 Nov 16
[PubMed PMID: 30446638]
[10]
Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinburgh, Scotland). 2019 May:116S():S66-S70. doi: 10.1016/j.tube.2019.04.012. Epub 2019 Apr 26
[PubMed PMID: 31076322]
[11]
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Oct 1:63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10
[PubMed PMID: 27516382]
Level 1 (high-level) evidence
[12]
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2020 Feb 14:69(1):1-11. doi: 10.15585/mmwr.rr6901a1. Epub 2020 Feb 14
[PubMed PMID: 32053584]
[13]
Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clinical pharmacokinetics. 1979 Nov-Dec:4(6):401-22
[PubMed PMID: 391461]
[14]
Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstetrics and gynecology. 2020 Jun:135(6):1444-1453. doi: 10.1097/AOG.0000000000003890. Epub
[PubMed PMID: 32459437]
[16]
Caraux-Paz P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the Elderly. Journal of clinical medicine. 2021 Dec 15:10(24):. doi: 10.3390/jcm10245888. Epub 2021 Dec 15
[PubMed PMID: 34945187]
[17]
Stettner M, Steinberger D, Hartmann CJ, Pabst T, Konta L, Hartung HP, Kieseier BC. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? Brain and behavior. 2015 Aug:5(8):e00326. doi: 10.1002/brb3.326. Epub 2015 May 29
[PubMed PMID: 26355945]
[18]
Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrobial agents and chemotherapy. 2001 Feb:45(2):382-92
[PubMed PMID: 11158730]
[19]
Shah R, Ankale P, Sinha K, Iyer A, Jayalakshmi TK. Isoniazid Induced Lupus Presenting as Oral Mucosal Ulcers with Pancytopenia. Journal of clinical and diagnostic research : JCDR. 2016 Oct:10(10):OD03-OD05
[PubMed PMID: 27891378]
[20]
Lee AYS. Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus. Immunological medicine. 2022 Dec:45(4):180-185. doi: 10.1080/25785826.2022.2060168. Epub 2022 Apr 6
[PubMed PMID: 35383534]
[21]
Constantinescu SM, Buysschaert B, Haufroid V, Broly F, Jadoul M, Morelle J. Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review. BMC nephrology. 2017 Sep 4:18(1):282. doi: 10.1186/s12882-017-0703-6. Epub 2017 Sep 4
[PubMed PMID: 28870161]
Level 3 (low-level) evidence
[22]
Adithan C, Subathra A. NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity. The Indian journal of medical research. 2016 May:143(5):542-4. doi: 10.4103/0971-5916.187101. Epub
[PubMed PMID: 27487996]
[23]
Suzuki A, Yuen NA, Ilic K, Miller RT, Reese MJ, Brown HR, Ambroso JI, Falls JG, Hunt CM. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regulatory toxicology and pharmacology : RTP. 2015 Aug:72(3):481-90. doi: 10.1016/j.yrtph.2015.05.004. Epub 2015 May 16
[PubMed PMID: 25988394]
[24]
Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug safety. 2002:25(2):111-33
[PubMed PMID: 11888353]
[25]
Durek C, Rüsch-Gerdes S, Jocham D, Böhle A. Sensitivity of BCG to modern antibiotics. European urology. 2000:37 Suppl 1():21-5
[PubMed PMID: 10575268]
[26]
Iwamoto S, Suzuki T, Sutani A, Kuraki T, Isobe T. [A case of atypical drug-induced hypersensitivity syndrome caused by isoniazid]. Kekkaku : [Tuberculosis]. 2012 Dec:87(12):777-82
[PubMed PMID: 23350519]
Level 3 (low-level) evidence
[27]
Denholm JT, McBryde ES, Eisen DP, Penington JS, Chen C, Street AC. Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study. Drug, healthcare and patient safety. 2014:6():145-9. doi: 10.2147/DHPS.S68837. Epub 2014 Oct 20
[PubMed PMID: 25364275]
[28]
Soobratty MR, Whitfield R, Subramaniam K, Grove G, Carver A, O'Donovan GV, Wu HH, Lee OY, Swaminathan R, Cope GF, Milburn HJ. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis. The European respiratory journal. 2014 May:43(5):1519-22. doi: 10.1183/09031936.00132613. Epub 2014 Jan 16
[PubMed PMID: 24435008]
[29]
Subbaraman R, Thomas BE, Kumar JV, Lubeck-Schricker M, Khandewale A, Thies W, Eliasziw M, Mayer KH, Haberer JE. Measuring Tuberculosis Medication Adherence: A Comparison of Multiple Approaches in Relation to Urine Isoniazid Metabolite Testing Within a Cohort Study in India. Open forum infectious diseases. 2021 Nov:8(11):ofab532. doi: 10.1093/ofid/ofab532. Epub 2021 Oct 17
[PubMed PMID: 35559123]
[30]
Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. British journal of clinical pharmacology. 2016 Jun:81(6):1030-6. doi: 10.1111/bcp.12885. Epub 2016 Feb 25
[PubMed PMID: 26773235]
[31]
Lee CM, Lee SS, Lee JM, Cho HC, Kim WS, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Early monitoring for detection of antituberculous drug-induced hepatotoxicity. The Korean journal of internal medicine. 2016 Jan:31(1):65-72. doi: 10.3904/kjim.2016.31.1.65. Epub 2015 Dec 28
[PubMed PMID: 26767859]
[32]
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR, ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. American journal of respiratory and critical care medicine. 2006 Oct 15:174(8):935-52
[PubMed PMID: 17021358]
[33]
Glatstein M, Carbell G, Scolnik D, Rimon A, Banerji S, Hoyte C. Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center. The American journal of emergency medicine. 2018 Oct:36(10):1775-1778. doi: 10.1016/j.ajem.2018.01.085. Epub 2018 Jan 31
[PubMed PMID: 29397257]
[34]
Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2017 Feb 1:21(2):129-139. doi: 10.5588/ijtld.16.0716. Epub
[PubMed PMID: 28234075]
[35]
Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harbor perspectives in medicine. 2015 Jan 8:5(5):a017822. doi: 10.1101/cshperspect.a017822. Epub 2015 Jan 8
[PubMed PMID: 25573773]
Level 3 (low-level) evidence